Saturday,
May 15 |
Sunday,
May 16 |
Monday,
May 17 |
Saturday,
May 15
| HALL 1.Alfama |
| 14:00 - 15:30 |
| Contrast Media Induced Nephropathy (CIN) |
| Chair: P. Persson, Berlin, Germany |
| Welcome |
| Introduction: What causes CIN? |
| P. Persson, Berlin, Germany |
| CIN: Critical review of the existing clinical evidence |
| M.A. Bettmann, New York, USA |
| Contrast induced alterations in regional kidney haemodynamics and oxygenation |
| S.N. Heyman, Jerusalem, Israel |
| How to avoid CIN: Guidelines from the European Society of Urogenital Radiology |
| H.S. Thomsen, Herlev, Denmark |
| General discussion, concluding remarks |
organised
by BRACCO, GUERBET, SCHERING |
| back to the top |
14:00
- 15:30 |
Progress
in Dialysis for diabetic patients |
Cardiovascular
risk management |
Chair:
F. Locatelli, Lecco, Italy |
Diabetes
and dialysis: epidemiological aspects |
F.
Locatelli, Lecco, Italy |
Blood
pressure management: experiences gained through international clinical
practices |
J.M.
Lopez Gomez, Madrid, Spain |
C.
Deziel, Montreal, Canada |
C.W.
McIntyre, Derby, United Kingdom |
Hospal
Research Funding: presentation of the awarded research projects |
F.
Locatelli, Lecco, Italy |
organised
by HOSPAL |
| back to the top |
| HALL 4.Rossio |
| 14:00 - 15:30 |
| Cystatin C: improving diagnosis and monitoring in kidney disease |
| Chair: R. Woitas, Bonn, Germany |
| Cystatin C for GFR estimation - Introduction |
| R. Woitas, Bonn, Germany |
| Cystatin C for GFR estimation in children and adolescents |
| A. Bökenkamp, Amsterdam, The Netherlands |
| Measurement of renal function in liver disease |
| R. Woitas, Bonn, Germany |
| Clinical value of serum and urinary Cystatin C in acute renal failure |
| S. Herget-Rosenthal, Essen, Germany |
organised
by DADE BEHRING |
| back to the top |
| HALL 1.Alfama |
| 16:00 - 17:30 |
| Enhancing renal anaemia management: new insights, best practice, future prospects |
| Chair: W.H Hörl, Vienna, Austria and J.A. Rossert, Paris, France |
| Welcome and introduction |
| W.H Hörl, Vienna, Austria |
| J.A. Rossert, Paris, France |
| Evaluating progress in the management of renal anaemia: results of the 2003 European Survey on Anaemia Management (ESAM) |
| C. Jacobs, Paris, France |
| A practical approach to improving renal anaemia therapy: clinical recommendations by the OPTA Working Group |
| Y. Vanrenterghem, Leuven, Belgium |
| Normalizing haemoglobin levels in early HD patients: lessons from an international randomized, double-blind, controlled trial |
| P.S. Parfrey, St. John’s, Canada |
| Understanding antibody-mediated PRCA |
| K.-U. Eckardt, Erlangen, Germany |
New horizons in the treatment of CKD: what does the future hold? |
| J. Knight, High Wycombe, United Kingdom |
| Panel discussion |
organised
by ORTHO BIOTECH |
| back to the top |
| HALL 3.Lapa |
| 16:00 - 17:30 |
| Calcium-based phosphate binders in the treatment of patients with chronic kidney disease |
| Chair: C. Nolan, San Antonio, USA |
| Is induced calcium toxicity an avoidable complication of phosphate binding in renal failure? |
| E.A. Friedman, New York, USA |
| Comparison of calcium-based phosphate binders and sevelamer hydrochloride in the context of ERA-EDTA and K/DOQI Mineral Metabolism Guidelines |
| C. Nolan, San Antonio, USA |
| Risks of chronic metabolic acidosis in patients with chronic kidney disease |
| J.D. Kopple, Torrance, USA |
| Daily dialysis in the treatment of refractory hyperphosphataemia and hyperparathyroidism |
| J.C. Ayus, San Antonio, USA |
organised
by BIOMUNE LIMITED |
| back to the top |
| HALL 4.Rossio |
| 16:00 - 17:30 |
| Kidney disease: improving global outcomes - Report on a New International Initiative - |
| Chair: G. Eknoyan, Houston, USA and N. Lameire, Ghent, Belgium |
| Why a global initiative? |
| G. Eknoyan, Houston, USA |
Initial accomplishments: four working groups |
| · Evidence rating |
| · CKD evaluation and classification |
| · Guideline database |
| · Guideline implementation |
| N. Lameire, Ghent, Belgium |
| Global bone and mineral initiative: a bridge to improving healthcare |
| Outcomes and quality of life |
| T. Drüeke, Paris, France |
| Future directions |
| F. Locatelli, Lecco, Italy |
organised
by K/DOQI - NATIONAL KIDNEY FOUNDATION |
| back to the top |
| HALL 5.Estrela |
| 16:00 - 17:30 |
| When is Fabry nephropathy reversible with enzyme replacement therapy? |
| Chair: R. Vanholder, Ghent, Belgium |
| Clinical panorama and diagnosis of Fabry disease |
| A. Mehta, London, United Kingdom |
| Renal manifestations in Fabry disease |
| F. Dehout, Charleroi, Belgium |
| Management of hypertension in Fabry disease |
| G. Sunder-Plassmann, Vienna, Austria |
| Clinical achievements with agalsidase alfa enzyme replacement therapy |
| A. Schwarting, Mainz, Germany |
| Discussion |
organised
by TKT |
| back to the top |
Sunday,
May 16
| MAIN HALL |
| 12:00 - 13:30 |
| Infection and inflammation in dialysis patients |
| Chair: E. Ritz, Heidelberg, Germany |
| Biofilm - a new perspective in dialysis |
| W. Costerton, Bozeman, USA |
| Avoiding bacterial contamination in dialysis fluids |
| R. Nystrand, Malmö, Sweden |
| Inflammatory response - mechanisms and consequences |
| E. Ritz, Heidelberg, Germany |
organised
by GAMBRO |
| back to the top |
| HALL 1.Alfama |
| 12:00 - 13:30 |
| Renal anaemia, risk factors and beyond – predictors of improved treatment outcomes in patients with CKD |
| Chair: F. Locatelli, Lecco, Italy and N. Lameire, Ghent, Belgium |
| Introduction |
| F. Locatelli, Lecco, Italy |
| Diabetes, anaemia and prognosis – can best practice improve outcomes? |
| N. Lameire, Ghent, Belgium |
| Cardiovascular risk and CKD – what is the impact of early anaemia treatment? |
| R. Foley, Minneapolis, USA |
| Maintaining target Hb levels – the benefits of SC administration |
| J. Kaufman, Boston, USA |
| Questions |
| All |
| Close |
| N. Lameire, Ghent, Belgium |
organised
by ROCHE |
| back to the top |
| HALL 2.Baixa |
| 12:00 - 13:30 |
| Shaping the future of phosphate management |
| Chair: J. Cannata-Andía, Oviedo, Spain |
| Introduction |
| J. Cannata-Andía, Oviedo, Spain |
| Clinical practice: are we getting it right? |
| J. Cannata-Andía, Oviedo, Spain |
| Lanthanum carbonate: a new solution to an old problem |
| The biological fate of lanthanum carbonate |
| S. Damment, Basingstoke, United Kingdom |
| Lanthanum and bone |
| M. De Broe, Antwerp, Belgium |
| Long-term success |
| A. Hutchison, Manchester, United Kingdom |
| Moving forward |
| J. Cunningham, London, United Kingdom |
| Panel discussion and closing remarks |
organised
by SHIRE |
| back to the top |
| HALL 3.Lapa |
| 12:00 - 13:30 |
| Controversies in iron management |
| Chair: I.C. Macdougall, London, United Kingdom and D. Van Wyck, Tucson, USA |
| Chairman’s welcome |
| I.C. Macdougall, London, United Kingdom |
| Target ferritin levels in the revised European Best Practice Guidelines on Anaemia Management: are they too high or too low? |
| D. Richardson, York, United Kingdom |
| Safety on IV iron preparations: |
| - are all preparations the same? |
| - is oxidative stress really a concern? |
| R.M. Schaefer, Münster, Germany |
| Can the usage of IV iron in CKD (pre-dialysis) patients avoid / postpone the need for erythropoietic therapy? |
| D. Silverberg, Tel Aviv, Israel |
| Discussion – Panel and Audience |
| Closing remarks |
| D. Van Wyck, Tucson, USA |
organised
by VIFOR |
| back to the top |
| HALL 4.Rossio |
| 12:00 - 13:30 |
| HDF Buffer Management |
| Chair: R. Vanholder, Ghent, Belgium and A. Santoro, Bologna, Italy |
| HDF: the European perspective |
| A.L.M. de Francisco, Santander, Spain |
| HDF on-line: clinical and technical overview |
| R. Greenwood, Stevenage, United Kingdom |
| Acetate Free: does acetate really matter? |
| B. Perrone, Pontoise, France |
| Biocompatibility of dialysate buffers |
| R. Coppo, Turin, Italy |
| Acetate free on-line hemodiafiltration: first clinical experience |
| F. Pizzarelli, Florence, Italy |
organised
by BELLCO |
| back to the top |
| HALL 5.Estrela |
| 12:00 - 13:30 |
| New options in optimising long-term outcomes after 10 years of tacrolimus |
| Chair: J.L. Reimao Pinto, Lisbon, Portugal |
| Introductory remarks |
| J.L. Reimao Pinto, Lisbon, Portugal |
| Confronting chronic graft nephropathy |
| K. Baboolal, Cardiff, UK |
| PTDM in perspective |
| J.P. van Hooff, Maastricht, The Netherlands |
| Corticosteroid-sparing strategies with tacrolimus |
| J.M. Campistol, Barcelona, Spain |
| Discussion |
| Concluding remarks |
| J.L. Reimao Pinto, Lisbon, Portugal |
organised
by FUJISAWA |
| back to the top |
Monday,
May 17
| MAIN HALL |
| 12:00 - 13:30 |
Intervention in the progression and consequences of Chronic Kidney Disease |
| Chair: J. Frazão, Porto, Portugal |
| Inflammation, oxidative stress and vascular calcification in CKD - are they partners in crime? |
| P. Stenvinkel, Stockholm, Sweden |
Prevention of vascular diseases through improved management of bone and mineral disorders in CKD patients |
| T. Drüeke, Paris, France |
Prevention of progression of Fabry disease in renal patients |
| B. Cianciaruso, Naples, Italy |
organised
by GENZYME |
| back to the top |
| HALL 1.Alfama |
| 12:00 - 13:30 |
| In the focus: heart and vessels in chronic kidney disease |
| Chair: F. Locatelli, Lecco, Italy |
| Cardiovascular risk factors - a challenge from the start of dialysis |
| Data from the MPO study |
| F. Locatelli, Lecco, Italy |
| Vascular stiffening – cardiovascular mortality |
| How can we break the link? |
| D. Goldsmith, London, United Kingdom |
| Management of increased atherogenicity in uraemia |
| C. Wanner, Würzburg, Germany |
organised
by FRESENIUS MEDICAL CARE |
| back to the top |
| HALL 3.Lapa |
| 12:00 - 13:30 |
| Pursuing better outcomes in chronic kidney disease patients |
| Chair: F. Carrera, Lisbon, Portugal |
| Introduction |
| F. Carrera, Lisbon, Portugal |
| Anaemia: a key mortality risk factor in chronic kidney disease patients |
| B. Pereira, Boston, USA |
| Extending the dosing intervals for anaemia patients |
| Y. Vanrenterghem, Leuven, Brussels |
| Assessing control of secondary hyperparathyroidism in Europe |
| J. Cannata-Andía, Oviedo, Spain |
| The value of bringing patients with secondary hyperparathyroidism to target |
| J. Cunningham, London, United Kingdom |
organised
by AMGEN |
| back to the top |
| HALL 4.Rossio |
| 12:00 - 13:30 |
| Advances in Vitamin D Therapy |
| Chair: J. Cannata-Andía, Oviedo, Spain |
| Welcome and Introduction |
| J. Cannata-Andía, Oviedo, Spain |
| Overview of Vitamin D analogs |
| E. Slatopolsky, St. Louis, USA |
| Vitamin D analogs and the treatment of Secondary Hyperparathyroidism |
| S. Sprague, Evanston, USA |
| Cardiovascular effects of Vitamin D |
| G. London, Fleury Merogis, France |
| Vitamin D and the prevention of morbidity and mortality |
| R.I. Thadhani, Boston, USA |
| Panel Discussion |
organised
by ABBOTT |
| back to the top |
| HALL 5.Estrela |
| 12:00 - 13:30 |
| Unpredicted events in dialysis: inflammation, oxidation, and endothelial changes - culprits or targets |
| Chair: E. Ritz, Heidelberg, Germany |
| Inflammation |
| E. Ritz, Heidelberg, Germany |
| Oxidation |
| G. Pertosa, Bari, Italy |
| Endothelial Changes |
| M. Bonomini, Chieti, Italy |
organised
by KURARAY |
| back to the top |